Nanodot–doped peptide hydrogel for antibacterial phototherapy and would healing

2022 ◽  
Author(s):  
Xuan Wang ◽  
Lin Qiu ◽  
Cheng Wang ◽  
Zihan Gao ◽  
Shuwen Zhou ◽  
...  
Keyword(s):  
Bacterial Infection ◽  
Healing Process ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Breeding Ground ◽  
Drug Resistant Bacteria ◽  
Chronic Trauma ◽  
Would Healing ◽  
Peptide Hydrogel

Bacterial infection of the wounds delays the healing process, increases the risk of becoming chronic trauma associated with pain and complications, and offers a breeding ground for drug-resistant bacteria. A...

scholarly journals Clinical observation and prognostic analysis of patients with Klebsiella pneumoniae bloodstream infection

2020 ◽  
Author(s):  
tongwen sun ◽  
shuguang zhang ◽  
ziyue yang ◽  
limin sun ◽  
zhenhua wang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Klebsiella Pneumoniae ◽  
Bacterial Infection ◽  
Bloodstream Infection ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Clinical Prognosis ◽  
Risk Of Death ◽  
Drug Resistant Bacteria ◽  
Epidemiological Characteristics

Abstract Background and Purpose: The clinical prognosis of Klebsiella pneumoniae bloodstream infection is poor, and the prevalence of drug-resistant bacteria makes clinical anti-infective treatment more challenging. This retrospective study evaluated the epidemiological characteristics of patients with Klebsiella pneumoniae, the risk factors for drug-resistant bacterial infection and death, and analyzed treatment options. Methods: Clinical data of 297 patients diagnosed with Klebsiella pneumoniae bacteremia between June 2014 and June 2019 were collected.Results: Intensive care unit hospitalization history, operation history, recent antibiotic use history, mechanical ventilation, and number of days hospitalized before bloodstream infection were found to be independent risk factors for drug-resistant bacterial infection. The risk of death for carbapenem-resistant Klebsiella pneumoniae infection was 2.942 times higher than that for carbapenem-sensitive Klebsiella pneumoniae infection. For extensively drug-resistant Klebsiella pneumoniae bacteremia patients, the mortality rate of combined anti-infective therapy was lower.Conclusions: Clinicians should pay attention to patients with high-risk drug-resistant bacteria infection and administer timely anti-infection treatment. The findings of this study may provide some suggestions for early identification and standardized treatment of patients with Klebsiella pneumoniae bacteremia.

scholarly journals Antimicrobial Resistance: Are we heading towards Post Antibiotic Era?

JMS SKIMS ◽  
2014 ◽  
Vol 17 (2) ◽  
pp. 48-49
Author(s):  
Bashir A Fomda
Keyword(s):  
Antimicrobial Resistance ◽  
Drug Development ◽  
Bacterial Infection ◽  
Antimicrobial Agents ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Inappropriate Use ◽  
New Drug ◽  
Drug Resistant Bacteria ◽  
Alexander Fleming

The discovery of penicillin in 1928 by Alexander Fleming , a magic antibiotic used for treatment of most of the bacterial infection marked the beginning of antibiotic era. With booming drug development a new drug was always available to treat increasing drug resistant bacteria. Between 1935 to 2003 fourteen classes of antibiotics were developed. However with the indiscriminate and inappropriate use of antibiotics, microbes developed mechanisms to elude the action of antimicrobial agents. JMS 2014;17(2):48-49

Novel Antibiotics from Marine Sources

2011 ◽  
Vol 4 (3) ◽  
pp. 1446-1461 ◽  
Author(s):  
E.A. Martis ◽  
G M Doshi ◽  
G V Aggarwal ◽  
P P Shanbhag
Keyword(s):  
Pharmaceutical Industry ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Terrestrial Life ◽  
New Antibiotics ◽  
Antibiotic Compounds ◽  
New Generation ◽  
Novel Antibiotics ◽  
Untapped Resource

With the emergence of newer diseases, resistant forms of infectious diseases and multi-drug resistant bacteria, it has become essential to develop novel and more effective antibiotics. Current antibiotics are obtained from terrestrial life or made synthetically from intermediates. The ocean represents virtually untapped resource from which novel antibiotic compounds can be discovered. It is the marine world that will provide the pharmaceutical industry with the next generation of antibiotics. Marine antibiotics are antibiotics obtained from marine organisms. Scientists have reported the discovery of various antibiotics from marine bacteria (aplasmomycin, himalomycins, and pelagiomycins), sponges (Ara C, variabillin, strobilin, ircinin-1, aeroplysin, 3,5-dibromo-4-hydroxyphenylacetamide), coelenterates (asperidol and eunicin), mollusks (laurinterol and pachydictyol), tunicates (geranylhydroquinone and cystadytins), algae (cycloeudesmol, aeroplysinin-1(+), prepacifenol and tetrabromoheptanone), worms (tholepin and 3,5-dibromo-4-hydroxybezaldehyde), and actinomycetes (marinomycins C and D). This indicates that the marine environment, representing approximately half of the global diversity, is an enormous resource for new antibiotics and this source needs to be explored for the discovery of new generation antibiotics. The present article provides an overview of various antibiotics obtained from marine sources.

Re-challenging antibiotic resistance with Daniel Berman

2020 ◽  
Author(s):  
Daniel Berman
Keyword(s):  
Bacterial Infections ◽  
Point Of Care ◽  
Healthcare Setting ◽  
Rapid Diagnostic Tests ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Global Threat ◽  
The Right ◽  
Point Of Care Tests

How can we prevent the rise of resistance to antibiotics? In this video, Daniel Berman,  Nesta Challenges, discusses the global threat of AMR and how prizes like the Longitude Prize can foster the development of rapid diagnostic tests for bacterial infections, helping to contribute towards reducing the global threat of drug resistant bacteria. Daniel outlines how accelerating the development of rapid point-of-care tests will ensure that bacterial infections are treated with the most appropriate antibiotic, at the right time and in the right healthcare setting.

Use of proton pump inhibitors and cholangitis complicated with multi‐drug resistant bacteria

2021 ◽  
Author(s):  
Ryunosuke Hakuta ◽  
Yousuke Nakai ◽  
Tsuyoshi Hamada ◽  
Yusuke Nomura ◽  
Tomotaka Saito ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria

scholarly journals Novel Seleno- and Thio-Urea Containing Dihydropyrrol-2-One Analogues as Antibacterial Agents

Antibiotics ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 321
Author(s):  
Shekh Sabir ◽  
Tsz Tin Yu ◽  
Rajesh Kuppusamy ◽  
Basmah Almohaywi ◽  
George Iskander ◽  
...  
Keyword(s):  
Antibacterial Activity ◽  
Antibiotic Resistance ◽  
Quorum Sensing ◽  
Antibacterial Agents ◽  
Inhibitory Concentration ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Positive Bacterium ◽  
Quorum Sensing Inhibition ◽  
Drug Resistant Bacteria

The quorum sensing (QS) system in multi-drug-resistant bacteria such as P. aeruginosa is primarily responsible for the development of antibiotic resistance and is considered an attractive target for antimicrobial drug discovery. In this study, we synthesised a series of novel selenourea and thiourea-containing dihydropyrrol-2-one (DHP) analogues as LasR antagonists. The selenium DHP derivatives displayed significantly better quorum-sensing inhibition (QSI) activities than the corresponding sulphur analogues. The most potent analogue 3e efficiently inhibited the las QS system by 81% at 125 µM and 53% at 31 µM. Additionally, all the compounds were screened for their minimum inhibitory concentration (MIC) against the Gram-positive bacterium S. aureus, and interestingly, only the selenium analogues showed antibacterial activity, with 3c and 3e being the most potent with a MIC of 15.6 µM.

Sign in / Sign up

Export Citation Format

Share Document